Table 1.
Demographic data at baseline and types of surgeries conducted for both cohorts. Others include evacuation of intracranial abscesses, deep tissue infections and reconstructions of anterior skull base defects. ∗Stereotactic biopsy without craniotomy. ASA – ayetylsalicylic acid; NOAC – new oral anticoagulants; P – level of significance. ∗Stereotactic biopsy without craniotomy. ASA – ayetylsalicylic acid; NOAC – new oral anticoagulants; P – level of significance.
| Study Cohort (N = 197) | Control Cohort (N = 197) | P | |
|---|---|---|---|
| Age (years) | |||
| Mean | 57 | 57 | .840 |
| Median | 57 | 56 | |
| Standard deviation | 16 | 14 | |
| Range | 19–97 | 19–84 | |
| Variance | 267 | 193 | |
| Female sex, n (%) | 101 (51) | 99 (52) | .920 |
| Surgery, n (%) | |||
| Benign tumor resection | 52 (26) | 53 (27) | .997 |
| Malign tumor resection | 80 (41) | 81 (41) | |
| Neurovascular surgery | 18 (9) | 18 (9) | |
| Hematoma evacuation | 2 (1) | 2 (1) | |
| Cranioplasty | 23 (12) | 24 (12) | |
| Shunt implantation | 6 (3) | 6 (3) | |
| Stereotactic biopsy∗ | 9 (5) | 9 (5) | |
| Others | 7 (4) | 4 (2) | |
| Preoperative Medication | |||
| ASA (%) | 25 (13) | 21 (11) | .556 |
| ASA + Clopidogrel (%) | 1 (0,5) | – | |
| ASA + NOAC (%) | 2 (1) | 1 (0.5) | |
| Clopidogrel (%) | – | – | |
| NOAC (%) | 8 (4) | 2 (1) | |
| Marcumar (%) | 1 (0.5) | 1 (0.5) | |